| 產(chǎn)品詳情 |
| Edit |   |
|---|
| Antigenic Specificity | Granzyme B |
|---|
| Clone | O94E6/GZMB |
|---|
| Host Species | Mouse |
|---|
| Reactive Species | human |
|---|
| Isotype | IgG2a |
|---|
| Format | purified |
|---|
| Size | 100 μg |
|---|
| Concentration | n/a |
|---|
| Applications | Western Blot (WB) |
|---|
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
|---|
| Description | Purified anti-Granzyme B. Granzyme B is a serine protease that is produced mainly by cytotoxic T cells (CTL) and natural killer (NK) cells. It plays an important role in cytotoxic lymphocyte-mediated apoptosis, chronic inflammation, and impaired wound healing. Granzyme B is packaged in cytoplasmic granules that are exocytosed towards a bound target cell, which subsequently activates multiple protein substrates that induce apoptosis. Perforin facilitates the transfer of Granzyme B into the target cell. Most circulating CD56+, CD8-, NK cells, and approximately half of circulating CD8+ T cells coexpress both Granzyme A and B. The activation of CD8+ and CD4+ T lymphocytes induce substantial expression of Granzyme B, but not Granzyme A. Recently, Granzyme B has been found to be produced by other cell types such as CD34+ hematopoietic progenitor cells, keratinocytes, basophils, mast cells, plasmacytoid dendritic cells, B cells, and smooth muscle cells. Elevated levels of Granzyme B are also found in some kinds of autoimmune diseases, type 1 diabetes, and cardiovascular diseases. |
|---|
| Immunogen | Recombinant fragment corresponding to amino acids 21-247 of Human Granzyme B produced in E. coli. |
|---|
| Other Names | Granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1, GZMB, CCP1, Asp-ase, CSPB, CTLA-1, CGL-1, CGL1 |
|---|
| Gene, Accession # | Gene ID: 3002 |
|---|
| Catalog # | 674302 |
|---|
| Price | |
|---|
| Order / More Info | Granzyme B Antibody from BIOLEGEND |
|---|
| Product Specific References | n/a |
|---|
| 產(chǎn)品資料 |
|
|